These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


2271 related items for PubMed ID: 18191065

  • 1. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW.
    Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
    [Abstract] [Full Text] [Related]

  • 2. Flexibility of rapid-acting insulin analogues in children and adolescents with diabetes mellitus.
    Danne T.
    Clin Ther; 2007; 29 Suppl D():S145-52. PubMed ID: 18191066
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Quality of life and treatment satisfaction in adults with Type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections.
    EQuality1 Study Group--Evaluation of QUALITY of Life and Costs in Diabetes Type 1, Nicolucci A, Maione A, Franciosi M, Amoretti R, Busetto E, Capani F, Bruttomesso D, Di Bartolo P, Girelli A, Leonetti F, Morviducci L, Ponzi P, Vitacolonna E.
    Diabet Med; 2008 Feb; 25(2):213-20. PubMed ID: 18201210
    [Abstract] [Full Text] [Related]

  • 5. A 2-way cross-over, open-labeled trial to compare efficacy and safety of insulin Aspart and Novolin R delivered with CSII in 21 Chinese diabetic patients.
    Bi YF, Zhao LB, Li XY, Wang WQ, Sun SY, Chen YH, Hong J, Su TW, Liu JM, Ning G.
    Chin Med J (Engl); 2007 Oct 05; 120(19):1700-3. PubMed ID: 17935674
    [Abstract] [Full Text] [Related]

  • 6. Type 1 diabetes mellitus: effective insulin strategies with less hypoglycemia.
    Bolli GB.
    Postgrad Med; 2004 Nov 05; 116(5 Suppl Exploring):13-20. PubMed ID: 19667675
    [Abstract] [Full Text] [Related]

  • 7. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness.
    Radermecker RP, Scheen AJ.
    Diabetes Metab Res Rev; 2004 Nov 05; 20(3):178-88. PubMed ID: 15133748
    [Abstract] [Full Text] [Related]

  • 8. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
    Jovanovic L, Giammattei J, Acquistapace M, Bornstein K, Sommermann E, Pettitt DJ.
    Clin Ther; 2004 Sep 05; 26(9):1492-7. PubMed ID: 15531011
    [Abstract] [Full Text] [Related]

  • 9. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
    Bruttomesso D, Crazzolara D, Maran A, Costa S, Dal Pos M, Girelli A, Lepore G, Aragona M, Iori E, Valentini U, Del Prato S, Tiengo A, Buhr A, Trevisan R, Baritussio A.
    Diabet Med; 2008 Mar 05; 25(3):326-32. PubMed ID: 18307459
    [Abstract] [Full Text] [Related]

  • 10. Clinical strategies for controlling peaks and valleys: type 1 diabetes.
    Bolli GB.
    Int J Clin Pract Suppl; 2002 Jul 05; (129):65-74. PubMed ID: 12166610
    [Abstract] [Full Text] [Related]

  • 11. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials.
    Pala L, Dicembrini I, Mannucci E.
    Acta Diabetol; 2019 Sep 05; 56(9):973-980. PubMed ID: 30945047
    [Abstract] [Full Text] [Related]

  • 12. Long-term benefits of continuous subcutaneous insulin infusion in children with Type 1 diabetes: a 4-year follow-up.
    Sulli N, Shashaj B.
    Diabet Med; 2006 Aug 05; 23(8):900-6. PubMed ID: 16911629
    [Abstract] [Full Text] [Related]

  • 13. Premixed insulin treatment for type 2 diabetes: analogue or human?
    Garber AJ, Ligthelm R, Christiansen JS, Liebl A.
    Diabetes Obes Metab; 2007 Sep 05; 9(5):630-9. PubMed ID: 17697056
    [Abstract] [Full Text] [Related]

  • 14. Fields of application of continuous subcutaneous insulin infusion in the treatment of diabetes and implications in the use of rapid-acting insulin analogues.
    Pitocco D, Rizzi A, Scavone G, Tanese L, Zaccardi F, Manto A, Ghirlanda G.
    Minerva Endocrinol; 2013 Sep 05; 38(3):321-8. PubMed ID: 24126552
    [Abstract] [Full Text] [Related]

  • 15. Glucose profiles in a type 1 diabetic patient successively treated with CSII using regular insulin, lispro and an implantable insulin pump.
    Catargi B, Breilh D, Roger P, Tabarin A.
    Diabetes Metab; 2000 May 05; 26(3):210-4. PubMed ID: 10880895
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: a meta-analysis.
    Monami M, Lamanna C, Marchionni N, Mannucci E.
    Exp Clin Endocrinol Diabetes; 2009 May 05; 117(5):220-2. PubMed ID: 19301231
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Type 1 diabetes control and pregnancy outcomes in women treated with continuous subcutaneous insulin infusion (CSII) or with insulin glargine and multiple daily injections of rapid-acting insulin analogues (glargine-MDI).
    Bruttomesso D, Bonomo M, Costa S, Dal Pos M, Di Cianni G, Pellicano F, Vitacolonna E, Dodesini AR, Tonutti L, Lapolla A, Di Benedetto A, Torlone E, Italian Group for Continuous Subcutaneous Insulin Infusion in Pregnancy.
    Diabetes Metab; 2011 Nov 05; 37(5):426-31. PubMed ID: 21474360
    [Abstract] [Full Text] [Related]

  • 20. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
    Hassan K, Rodriguez LM, Johnson SE, Tadlock S, Heptulla RA.
    Pediatrics; 2008 Mar 05; 121(3):e466-72. PubMed ID: 18299307
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 114.